Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. (clinicaltrials.gov) - Sep 18, 2026 - P1 | N=22 | Completed | Sponsor: National Health Research Institutes, Taiwan | Active, not recruiting ➔ Completed
Trial completion • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Primary Central Nervous System Lymphoma
|